Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Alnylam Pharmace. diskutieren

Alnylam Pharmace.

WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

345,80 €
-3,03 %

Einschätzung Buy
Rendite (%) -11,99 %
Kursziel 492,77
Veränderung
Endet am 10.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $570.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,00 %
Kursziel 407,06
Veränderung
Endet am 13.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at JPMorgan Chase & Co. from $475.00 to $473.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -17,31 %
Kursziel 457,16
Veränderung
Endet am 17.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Truist Financial Corporation from $459.00 to $535.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -11,11 %
Kursziel 472,69
Veränderung
Endet am 30.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Jefferies Financial Group Inc. from $550.00 to $549.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -12,59 %
Kursziel 455,43
Veränderung
Endet am 31.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Barclays PLC from $460.00 to $527.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -12,59 %
Kursziel 422,59
Veränderung
Endet am 31.10.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $489.00 price target on the stock, up previously from $449.00.
Ratings data for ALNY provided by MarketBeat

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,04 %
Kursziel 495,27
Veränderung
Endet am 04.11.26

Alnylam Pharmaceuticals (NASDAQ:ALNY) was given a new $570.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat